AtriCure, Inc. (NASDAQ:ATRC) Director B Kristine Johnson purchased 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The stock was bought at an average cost of $18.36 per share, with a total value of $27,540.00. Following the acquisition, the director now owns 10,969 shares in the company, valued at approximately $201,390.84. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of AtriCure, Inc. (NASDAQ:ATRC) traded down $0.05 on Friday, reaching $18.60. 215,000 shares of the company’s stock traded hands, compared to its average volume of 201,469. AtriCure, Inc. has a 52 week low of $14.78 and a 52 week high of $25.18. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.65 and a current ratio of 2.28.

AtriCure (NASDAQ:ATRC) last announced its earnings results on Wednesday, November 1st. The medical device company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.02. AtriCure had a negative net margin of 19.40% and a negative return on equity of 20.28%. The company had revenue of $42.20 million for the quarter, compared to analysts’ expectations of $43.44 million. During the same quarter in the previous year, the company posted ($0.21) EPS. The firm’s quarterly revenue was up 10.1% on a year-over-year basis. analysts forecast that AtriCure, Inc. will post -0.96 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.thecerbatgem.com/2017/11/11/b-kristine-johnson-acquires-1500-shares-of-atricure-inc-atrc-stock.html.

A number of institutional investors and hedge funds have recently made changes to their positions in ATRC. US Bancorp DE boosted its stake in AtriCure by 152.1% during the 2nd quarter. US Bancorp DE now owns 4,202 shares of the medical device company’s stock worth $102,000 after purchasing an additional 2,535 shares during the last quarter. Sei Investments Co. boosted its stake in AtriCure by 75.5% during the 2nd quarter. Sei Investments Co. now owns 6,933 shares of the medical device company’s stock worth $168,000 after purchasing an additional 2,983 shares during the last quarter. Legal & General Group Plc boosted its stake in AtriCure by 3.8% during the 2nd quarter. Legal & General Group Plc now owns 8,528 shares of the medical device company’s stock worth $208,000 after purchasing an additional 312 shares during the last quarter. Tudor Investment Corp ET AL acquired a new stake in AtriCure during the 2nd quarter worth $253,000. Finally, Commerce Bank acquired a new stake in AtriCure during the 2nd quarter worth $266,000. 81.34% of the stock is currently owned by institutional investors.

Several equities research analysts recently commented on the stock. Canaccord Genuity reissued a “buy” rating and issued a $28.00 price target on shares of AtriCure in a report on Monday, October 9th. BidaskClub lowered shares of AtriCure from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Needham & Company LLC cut their price target on shares of AtriCure from $26.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, November 2nd. Zacks Investment Research raised shares of AtriCure from a “sell” rating to a “hold” rating in a report on Monday, October 2nd. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $25.00 price target on shares of AtriCure in a report on Sunday, July 30th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $25.00.

AtriCure Company Profile

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Receive News & Stock Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related stocks with our FREE daily email newsletter.